'Real world survey' of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

Autor: Jibing Chen, Shu-Cun Qin, Kecheng Xu, Tian-Yu Lu, Xiao-Feng Kong, Feng Mu, Youyong Lv, Xue-Jun Sun
Rok vydání: 2019
Předmět:
Male
Research Report
0301 basic medicine
hydrogen inhalation therapy
physical status
Gastroenterology
0302 clinical medicine
Neoplasms
Surveys and Questionnaires
advanced cancer
Stage (cooking)
Aged
80 and over
Inhalation
Middle Aged
life quality
Treatment Outcome
030220 oncology & carcinogenesis
Female
Safety
medicine.symptom
Research Article
Adult
medicine.medical_specialty
Neuroscience (miscellaneous)
Anorexia
Young Adult
03 medical and health sciences
Pancreatic cancer
Internal medicine
Administration
Inhalation
Biomarkers
Tumor
medicine
Humans
Lung cancer
Aged
Retrospective Studies
Tumor marker
business.industry
real world survey
Cancer
medicine.disease
Advanced cancer
030104 developmental biology
Anesthesiology and Pain Medicine
disease control rate
tumor marker
clinical rehabilitation
business
tumor stage
Follow-Up Studies
Hydrogen
Zdroj: Medical Gas Research
ISSN: 2045-9912
DOI: 10.4103/2045-9912.266985
Popis: Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the “real world evidence” method. After 3–46 months of follow-up, 12 patients died in stage IV. After 4 weeks of hydrogen inhalation, patients reported significant improvements in fatigue, insomnia, anorexia and pain. Furthermore, 41.5% of patients had improved physical status, with the best effect achieved in lung cancer patients and the poorest in patients with pancreatic and gynecologic cancers. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13–45 days (median 23 days) after hydrogen inhalation in 36.2%. The greatest marker decrease was in achieved lung cancer and the lowest in pancreatic and hepatic malignancies. Of the 80 cases with tumors visible in imaging, the total disease control rate was 57.5%, with complete and partial remission appearing at 21–80 days (median 55 days) after hydrogen inhalation. The disease control rate was significantly higher in stage III patients than in stage IV patients (83.0% and 47.7%, respectively), with the lowest disease control rate in pancreatic cancer patients. No hematological toxicity was observed although minor adverse reactions that resolved spontaneously were seen in individual cases. In patients with advanced cancer, inhaled hydrogen can improve patients’ quality-of-life and control cancer progression. Hydrogen inhalation is a simple, low-cost treatment with few adverse reactions that warrants further investigation as a strategy for clinical rehabilitation of patients with advanced cancer. The study protocol received ethical approval from the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval number: Fuda20181207).
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje